See more : Motivating the Masses, Inc. (MNMT) Income Statement Analysis – Financial Results
Complete financial analysis of Steep Hill Inc. (STPH.CN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Steep Hill Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Tamai Steamship Co., Ltd. (9127.T) Income Statement Analysis – Financial Results
- Red Metal Resources Ltd. (RMESF) Income Statement Analysis – Financial Results
- GBS Inc. (GBS) Income Statement Analysis – Financial Results
- China Mobile Limited (0941.HK) Income Statement Analysis – Financial Results
- Citizens Commerce Bancshares, Inc. (CCVS) Income Statement Analysis – Financial Results
Steep Hill Inc. (STPH.CN)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.steephill.com
About Steep Hill Inc.
Steep Hill Inc., a cannabis science and technology company, provides laboratory testing, quality assurance, and data analytics services in Canada and the United States. It offers analytical testing services, such as cannabinoids, terpenes, pesticides analysis, mycotoxins analysis, heavy metals analysis, residual solvents analysis, microbial analysis, foreign matter inspection, moisture content analysis, water activity analysis, vitamin E acetate, homogeneity testing, and hemp analysis, as well as consulting services in the areas of analytical testing, cannabis testing regulations, test methods, laboratory information management systems, and product quality and safety. The company was formerly known as Cannabis Clonal Corporation and changed its name to Steep Hill Inc. in February 2022. Steep Hill Inc. was founded in 2008 and is based in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 1.18M | 938.57K | 0.00 | 0.00 |
| Cost of Revenue | 16.64K | 500.00K | 0.00 | 118.78K | 14.58K |
| Gross Profit | -16.64K | 675.48K | 938.57K | -118.78K | -14.58K |
| Gross Profit Ratio | 0.00% | 57.46% | 100.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 535.08K | 401.75K | 24.41K | 0.00 |
| General & Administrative | 414.62K | 1.14M | 1.75M | 914.49K | 38.28K |
| Selling & Marketing | 68.03K | 36.86K | 329.12K | 180.87K | 327.02K |
| SG&A | 482.65K | 2.21M | 3.38M | 1.81M | 367.66K |
| Other Expenses | 0.00 | 209.33K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 482.65K | 5.41M | 5.43M | 1.97M | 368.65K |
| Cost & Expenses | 482.65K | 5.41M | 5.43M | 2.09M | 383.23K |
| Interest Income | 49.27K | 45.41K | 52.55K | 26.25K | 6.60K |
| Interest Expense | 0.00 | 45.41K | 52.55K | 0.00 | 0.00 |
| Depreciation & Amortization | 16.64K | 500.00K | 521.90K | 138.20K | 382.25K |
| EBITDA | -444.66K | -3.73M | -3.97M | -1.95M | 0.00 |
| EBITDA Ratio | 0.00% | -140.51% | -316.01% | 0.00% | 0.00% |
| Operating Income | -482.65K | -2.07M | -3.32M | -2.07M | -382.25K |
| Operating Income Ratio | 0.00% | -175.95% | -353.72% | 0.00% | 0.00% |
| Total Other Income/Expenses | 19.55K | -2.71M | -697.36K | 1.48K | 6.60K |
| Income Before Tax | -463.09K | -4.28M | -4.54M | -2.12M | -376.63K |
| Income Before Tax Ratio | 0.00% | -363.98% | -484.17% | 0.00% | 0.00% |
| Income Tax Expense | -23.66K | 23.66K | -13.72K | -34.87K | 5.62K |
| Net Income | 793.30K | -4.31M | -4.53M | -2.08M | -376.63K |
| Net Income Ratio | 0.00% | -366.62% | -482.70% | 0.00% | 0.00% |
| EPS | -0.02 | -0.27 | -0.75 | -0.80 | -0.23 |
| EPS Diluted | -0.03 | -0.27 | -0.75 | -0.80 | -0.23 |
| Weighted Avg Shares Out | 29.23M | 15.78M | 6.05M | 2.59M | 1.61M |
| Weighted Avg Shares Out (Dil) | 16.19M | 15.78M | 6.05M | 2.59M | 1.61M |
Source: https://incomestatements.info
Category: Stock Reports